Integrating Molecular Oncology into Therapeutic Strategies for Prostate Cancer

European Urology, Supplements

Volumn 8, Issue 3, 2009, Pages 114-119

  Gross Goupil, Marine ^a   Massard, Christophe ^a   Fizazi, Karim ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Androgen deprivation; Angiogenesis; Bone metastasis; Prostate cancer

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; ANDROGEN RECEPTOR; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CORTICOSTEROID; DENOSUMAB; DIETHYLSTILBESTROL; DOCETAXEL; ERLOTINIB; ESTRAMUSTINE PHOSPHATE; EXABEPILONE; FLUTAMIDE; GEFITINIB; HYDROCORTISONE; KETOCONAZOLE; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; PACLITAXEL; PREDNISONE; RADIOISOTOPE; RADIUM 223; SAMARIUM 153; SORAFENIB; STRONTIUM 89; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VINBLASTINE; ZOLEDRONIC ACID;

BONE METASTASIS; CARDIOTOXICITY; CLINICAL TRIAL; CYTOTOXICITY; DRUG MECHANISM; DRUG TARGETING; EDEMA; HEADACHE; HUMAN; HYPOKALEMIA; NOSE CONGESTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; THROMBOSIS;

EID: 57049096422     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2008.11.002     Document Type: Review

References (29)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5, version 2.0. Lyon, France: IARC Press; 2004.
2. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14 (1996) 1756-1764
3. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
4. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
5. Nelson W.G., De Marzo A.M., and Isaacs W.B. Prostate cancer. N Engl J Med 349 (2003) 366-381
6. Berthold D.R., Sternberg C.N., and Tannock I.F. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol 23 (2005) 8247-8252
7. Oh W.K. The evolving role of estrogen therapy in prostate cancer. Clin Prostate Cancer 1 (2002) 81-89
8. Ryan C.J., Rosenberg J., Lin A., Valiente J., Kim J., and Small E.J. Phase I evaluation of abiraterone acetate (CB7630), a 17 alpha hydroxylase C17,20-Lyase inhibitor in androgen-independent prostate cancer (AiPC). J Clin Oncol 25 (2007) 5064
9. Attard G., Yap T.A., Reid A.H., et al. Phase I study of continuous oral dosing of an irreversible CYP17 inhibitor, abiraterone (A), in castration refractory prostate cancer (CRPC) patients (p) incorporating the evaluation of androgens and steroid metabolites in plasma and tumor. J Clin Oncol 25 (2007) 5063
10. Khandwala H.M., Vassilopoulou-Sellin R., Logethetis C.J., and Friend K.E. Corticosteroid-induced inhibition of adrenal androgen production in selected patients with prostate cancer. Endocr Pract 7 (2001) 11-15
11. Fossa S.D., Slee P.H., Brausi M., et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 19 (2001) 62-71
12. Small E.J., Halabi S., Dawson N.A., et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22 (2004) 1025-1033
13. Savarese D.M., Halabi S., Hars V., et al. Phase II study of docetaxel, estramustine and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 19 (2001) 2509-2516
14. Sinibaldi V.J., Carducci M.A., Moore-Cooper S., Laufer M., Zahurak M., and Eisenberger M.A. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 94 (2002) 1457-1465
15. Fizazi K., Le Maitre A., Hudes G., et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 8 (2007) 994-1000
16. Morris C.D., Rose A., Curwen J., Hughes A.M., Wilson D.J., and Webb D.J. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer 92 (2005) 2148-2152
17. James N.D., Borre M., Zonnenberg B., et al. ZD4054, a potent, specific endothelin A receptor antagonist, improves overall survival in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer (HRPC) and bone metastases. Eur J Cancer Suppl 5 (2007) 3 abstract 3LB
18. Serafini A.N., Houston S.J., Harrison K.A., et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 16 (1998) 1574-1581
19. Porter A.T., McEwan A.J., Erlich L.E., et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25 (1993) 805-813
20. Nilsson S., Franzén L., Bruland O.S., et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 8 (2007) 587-594
21. Tu S.M., Kim J., Logothetis C.J., et al. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol 23 (2005) 7904-7910
22. Fizazi K, Beuzeboc P, Lumbroso J, et al. A prospective phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol. In press.
23. Saad F., Gleason D.M., Zheng M., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 (2004) 879-882
24. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
25. Roodman G.D. Biology of osteoclast activation in cancer. J Clin Oncol 19 (2001) 3562-3571
26. Fizazi K, Lipton A, Mariette X, et al. A randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasm after intravenous bisphosphonates. J Clin Oncol. In press.
27. Aragon-Ching J.B., and Dahut W.L. The role of angiogenesis inhibitors in prostate cancer. Cancer J 14 (2008) 20-25
28. Vergis R., Corbishley C.M., Parker C., et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 9 (2008) 342-351
29. Kerr D.J. Targeting angiogenesis in cancer: clinical development of bevacizumab. Nat Clin Pract Oncol 1 (2004) 39-43